_edited.png)
Longwood Healthcare Leaders Fall Conference
September 18 - 19, 2023
BioPharma industry leaders will convene in person at the Joseph B. Martin Conference Center at Harvard Medical School for an off-the-record networking and brainstorming forum focused on accelerating the translation of discoveries into medicines to help patients.
Conference participants are invited to attend a cocktail reception at the close of each day of the conference, 5 – 7 pm
Featured Speakers
Featured Firesides
Academia
R&D Leaders
BioPharma CEOs
BD & Strategy
Longwood Portfolio
Agenda
Day 1
7:30 am
LONGWOOD FUND INTRODUCTION
Christoph Westphal, General Partner, Longwood Fund
8:00 am
PHARMA PIPELINE SOURCING
Adam Feire¸ Global Head Search & Evaluation, Novartis
Sasha Huhalov, Head, Oncology Search and Evaluation, Takeda
Aakanksha Khandelwal, Global Commercial Lead, Oncology, Daiichi Sankyo
Tonya Villafana, Global Infection Franchise Head, Vaccines & Immune Therapies, AstraZeneca
Moderator: Anita Meiklejohn, Principal, Fish & Richardson
REGISTRATION & NETWORKING BREAKFAST
8:30 am
ALIGNING PRIORITIES FOR THE PARTNERSHIP
Vanessa Almendro, Head, Innovation, Danaher
Al Beardsley, COO, Galera Therapeutics
Robert Blum, CEO, Cytokinetics
Devyn Smith, CEO, Arbor Biotech
Moderator: Daniela Iwanski, VP, Executive and Board Recruiting, Govig
9:00 am
REGULATORY & INDUSTRY ROUNDTABLE
Peter Marks, Director, CBER, FDA
David Redfern, President, Corporate Development, GSK
Moderator: Christoph Westphal, General Partner, Longwood Fund
9:20 am
POLICY IMPACT ON INNOVATION
Meg Alexander, Chief Strategy and Corporate Affairs Officer, Ovid
Juliette Han, CFO & COO, Cambrian
Rachid Izzar, EVP, Head, Global Product Strategy & Commercialization, Biogen
Elizabeth Jeffords, CEO, Iolyx
Moderator: Jocelyn Ulrich, Deputy VP, Policy & Research, PhRMA
9:50 am
NETWORKING BREAK
10:20 am
INNOVATION IN CLINICAL TRIAL DESIGN
Rachel Humphrey, CEO, Normunity
Jak Knowles, CEO, Affini-T Therapeutics
Kinnari Patel, President & COO, Rocket Pharma
Amanda Wagner, CEO, Immunitas
Moderator: Zhen Su, CEO, Marengo Therapeutics
10:50 am
ENSURING HEALTH EQUITY & ACCESS
Ruxandra Draghia-Akli, Global Head, Global Public Health R&D, Janssen
Anne Klibanski, President & CEO, Mass General Brigham
Kabir Nath, CEO, Compass Pathways
Cindy Perettie, EVP, Kite Pharma
Moderator: Sheila Mikhail, Co-Founder, AskBio
11:20 am
FIRESIDE CHAT
Lew Cantley, Professor, Cell Biology, Harvard Medical School
George Daley, Dean, Harvard Medical School
Moderator: Christoph Westphal, General Partner, Longwood Fund
11:40 am
DRUG DISCOVERY SCIENCES
Laurent Audoly, CEO, Ruptakine
Chris Gibson, CEO, Recursion Pharmaceuticals
Jason Kelly, CEO, Ginkgo Bioworks
Moderator: Markus Haeberlein, SVP, Head, Research, Alkermes
12:10 pm
NETWORKING LUNCHEON
1:00 pm
R&D TRANSFORMATION
John Lepore, Head, Research, GlaxoSmithKline
John Renger, CSO, Cerevel
Kailash Swarna, Managing Director, Accenture
Tadaaki Taniguchi, CMO, Astellas
Brian Vandahl, SVP, Head, Global Research Technologies, Novo Nordisk
Moderator: Jane Wilkinson, Executive Director, Koch Institute at MIT
1:30 pm
DEAL MAKING FORECAST
Jennifer Cayer, CBO, Pulmocide
Thaminda Ramanayake, CBO, Affini-T Therapeutics
Beth Shafer, CBO, Voyager Therapeutics
Lynne Sullivan, CFO & Head, Corporate Development, Unity Biotechnology
Moderator: Bob Silverman, CBO, Turbine
2:00 pm
RARE DISEASE INNOVATION
PJ Brooks, Deputy Director, Office of Rare Diseases Research, NCATS, NIH
Rachelle Jacques, CEO, Akari Therapeutics
Bill Mezzanotte, Global, Head, R&D & CMO, CSL
Gilmore O’Neill, CEO, Editas Medicine
Moderator: Martin Mackay, Executive Chair & Co-Founder, Rallybio
2:30 pm
NETWORKING BREAK
3:00 pm
GETTING TO REGULATORY APPROVAL
Peter Hutt, General Counsel (former), FDA
Thomas Lonngren, Chair, Egetis Therapeutics AB; Executive Director (former), EMA
Stef Schutte, EVP, Head, Regulatory Affairs, Astellas
Moderator: Bill Lundberg, CEO, Merus
3:30 pm
FIRESIDE CHAT
Steve Elledge, Professor, Genetics, Harvard Medical School
Bill Kaelin, Sidney Farber Professor of Medicine, Dana-Farber Cancer Institute
Tim Springer, Latham Family Professor, Harvard Medical School
Moderator: Christoph Westphal, General Partner, Longwood Fund
4:00 pm
CROSS-CULTURAL COLLABORATION
Hank Safferstein, CEO, Generian
Ramona Sequeira, President, Global Portfolio Division, Takeda
Matt Stober, CEO, Abzena
Dan Wolf, SVP, Strategy & BD, Baxter
Moderator: Joe Payne, CEO, Arcturus Therapeutics
4:30 pm
DEVELOPING THE SYNDICATE
Christine Brennan, Managing Director, Vertex Ventures
Ansbert Gadicke, Managing Director, MPM Capital
Alaa Halawa, Executive Director, Mubadala
Omar Khalil, Partner, Sante Ventures
Moderator: David Steinberg, General Partner, Longwood Fund
5:00 pm
COCKTAIL RECEPTION
Day 2
7:00 am
REGISTRATION & NETWORKING BREAKFAST
7:30 am
LONGWOOD FUND INTRODUCTION
David Steinberg, General Partner, Longwood Fund
8:00 am
R&D COLLABORATION
Brian Fenton, CEO, Photys
Iris Grossman, Chief Therapeutics Officer, Eleven Therapeutics
Roger Palframan, Head, Research, US, UCB
Uli Stilz, Head, Bio Innovation Hub, Novo Nordisk
Matt Tremblay, CEO, Blackbird Labs
Moderator: Errik Anderson, CEO, Alloy Therapeutics
8:30 am
INNOVATIVE COMMERCIAL MODELS
Arpa Garay, CCO, Moderna
Eddie Martucci, CEO, Akili Interactive
Mike Shine, SVP, Commercial, Ocugen
Jason Tardio, Chief Operating Officer, Ovid
Moderator: Brian Fox, President, Commercial, Klick
9:00 am
AGE OF -OMICS
Fabrice Chouraqui, CEO, Cellarity
George Church, Professor, Genetics, Harvard Medical School
Elliot Ehrich, CMO, Life Mine Therapeutics
Li Peng, CSO, Palleon Pharmaceuticals
Moderator: Saul Kato, CEO, Herophilus
9:30 am
FIRESIDE CHAT
Rochelle Walensky, Director, CDC (2021-2023)
Moderator: Christoph Westphal, General Partner, Longwood Fund
9:50 am
NETWORKING BREAK
10:20 am
MANAGING THE RUNWAY
Carl Firth, CEO, ASLAN Pharmaceuticals
Luba Greenwood, CEO, Kojin Therapeutics
Nenad Grmusa, CEO, DEM Biopharma
Axel Hoos, CEO, Scorpion Therapeutics
Moderator: Brian McVeigh, Chairman, CEO and Co-Founder, Code Biotherapeutics
10:50 am
KEEPING THE PATIENT AT THE CENTER
Brian Alexander, CEO, Foundation Medicine
Al Gianchetti, CEO, XyloCor
Laurie Glimcher, CEO, Dana-Farber Cancer Institute
Ivana Magovcevic-Liebisch, CEO, Vigil Neuroscience
Moderator: Maria Whitman, Managing Partner, Global Commercialization Strategy, ZS Associates
11:20 am
TARGETED M&A
Andrew Davis, CBO, Ironwood Pharmaceuticals
Mark McKenna, CEO, Prometheus
Matt Roden, CEO, Aktis Oncology
Moderator: Chris Roop, Co-Head, M&A Group, Jefferies
11:50 am
ADVANCING RESEARCH INTO THE CLINIC
Jennifer Michaelson, CSO, Cullinan Oncology
Joel Schneider, CEO, Carbon Biosciences
Kai Wucherpfennig, Chair, Cancer Immunology and Virology, Dana-Farber Cancer Institute
Moderator: Catherine Pagliarulo, VP, Science & Technology, Alexandria Real Estate Equities
12:20 pm
NETWORKING LUNCHEON
1:00 pm
FOUNDATIONAL PARTNERING STRATEGY
Debbie Drane, SVP Global Commercial Development & TA Strategy, CSL Behring
Trevor Martin, CEO, Mammoth Biosciences
Chad Robins, CEO, Adaptive Biotech
Heather Wasserman, COO & CBO, Remix Therapeutics
Moderator: Jason Cole, CEO, SalioGen Therapeutics
1:30 pm
CURRENT STATE OF TALENT RECRUITMENT & RETENTION
Amira Barkal, Chief Development Officer, Pheast
Paul Froisland, SVP and Head of Human Resources, Senda Biosciences
Phil Vickers, CEO, Solu Therapeutics
Krishnan Viswanadhan, President & COO, Be Bio
Moderator: Cissy Young, Partner, Catalyst Advisors
2:00 pm
FIRESIDE CHAT
Dave Reese, EVP, R&D, Amgen
Priya Singhal, EVP & Head, Development & Interim Head of Research, Biogen
Moderator: Colin Hill, CEO, Aitia
2:20 pm
THE NEXT WAVE OF TARGETED THERAPIES
Kyle Holen, SVP, Head, Development, Therapeutics & Oncology, Moderna
Matt Henn, CSO, Seres Therapeutics
Gavin MacBeath, CEO, TScan
Moderator: Chen Schor, CEO, Adicet Bio
2:50 pm
NETWORKING BREAK
3:25 pm
EXTERNAL INNOVATION
Kathy Fernando, SVP, Head, Pfizer Ignte & Pfizer CentreOne
Michael Flaschen, SVP, Head, Global External Innovation, Daiichi Sankyo
Ariel Katz, CEO, H1
Ernesto Martinez, Head, Corporate Development & Innovation, MassChallenge
Shanshan Xu, Global Head, External Innovation, BioNTech
Moderator: Michal Preminger, Head, Innovation, E. North America, Johnson & Johnson
4:00 pm
PIPELINE PRIORITIZATION
Lori Grosso, Global Clinical Development Lead, Tevogen
Johan Luthman, Head, R&D, Lundbeck
Rick Morgan, CSO, Be Bio
Simona Skerjanec, SVP & Global Therapeutic Area Head, Neuroscience & Rare Diseases, Roche
Moderator: Lisa Ricciardi, CEO, Cognition Therapeutics
4:30 pm
INVESTMENT OUTLOOK
Ness Bermingham, Operating Partner, Khosla Ventures
Michelle Detwiler, Managing Partner, Biospring
Mike Ehlers, CSO & Venture Partner, Apple Tree Partners
Moderator: Aleks Radovic-Moreno, Partner, Longwood Fund
5:00 pm
COCKTAIL RECEPTION
Speaking Faculty
Cocktail Reception
Conference participants are invited to attend a cocktail reception at the close of each day of the conference, 5 – 7 pm
Venue
Harvard Medical School – Joseph B. Martin Conference Center
3rd Floor Rotunda
77 Avenue Louis Pasteur
Boston, MA 02155
.png)
.jpg){kind=logo}
